Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 19/20 | 0.68 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.68 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4819651 | 0.89 | MAPK14 (0.74) | MAPK14HSPB1 | |
| SCHEMBL5374027 | 0.87 | MAPK14 (0.65) | MAPK14HSPB1NPC1 | |
| SCHEMBL4822705 | 0.87 | MAPK14 (0.72) | MAPK14HSPB1 | |
| SCHEMBL4811975 | 0.86 | MAPK14 (0.71) | MAPK14HSPB1 | |
| SCHEMBL5380271 | 0.86 | MAPK14 (0.64) | MAPK14HSPB1NPC1 | |
| SCHEMBL4821373 | 0.83 | MAPK14 (0.67) | MAPK14HSPB1 | |
| SCHEMBL4816500 | 0.83 | MAPK14 (0.67) | MAPK14HSPB1NPC1 | |
| Gw743024X SCHEMBL4817886 | 0.81 | MAPK14 (1.00) | MAPK14HSPB1 | |
| SCHEMBL4701504 | 0.81 | MAPK14 (0.69) | MAPK14HSPB1NPC1 | |
| SCHEMBL5641957 | 0.81 | MAPK14 (0.66) | MAPK14HSPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7432289-B2 | 5-Acylamino-1,1′-biphenyl-4-carboxamide derivatives and their use as P38 kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2008-10-07 | — | — | US | claimed |
| US-7432289-B2 | 5-Acylamino-1,1′-biphenyl-4-carboxamide derivatives and their use as P38 kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2008-10-07 | — | — | US | disclosed |
| US-20040242868-A1 | 5-acylamino-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242868-A1 | 5-acylamino-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors | MAPK1, MAP3K1, MAPK7 | MAPK14 17/4885HSPB1 1461/4885NPC1 1611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.